163 related articles for article (PubMed ID: 12120885)
1. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis.
Brigidi P; Swennen E; Rizzello F; Bozzolasco M; Matteuzzi D
J Chemother; 2002 Jun; 14(3):290-5. PubMed ID: 12120885
[TBL] [Abstract][Full Text] [Related]
2. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci.
DuPont HL; Jiang ZD
Clin Microbiol Infect; 2004 Nov; 10(11):1009-11. PubMed ID: 15522005
[TBL] [Abstract][Full Text] [Related]
3. Rifaximin--a novel antimicrobial for enteric infections.
Huang DB; DuPont HL
J Infect; 2005 Feb; 50(2):97-106. PubMed ID: 15667909
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative.
Hoover WW; Gerlach EH; Hoban DJ; Eliopoulos GM; Pfaller MA; Jones RN
Diagn Microbiol Infect Dis; 1993 Feb; 16(2):111-8. PubMed ID: 8385592
[TBL] [Abstract][Full Text] [Related]
5. Rifaximin: a nonabsorbed oral antibiotic.
Baker DE
Rev Gastroenterol Disord; 2005; 5(1):19-30. PubMed ID: 15741929
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the in vitro susceptibility of rifaximin versus norfloxacin against multidrug resistant bacteria in a hospital setting. A proof-of-concept study for use in advanced cirrhosis.
Ramos JM; Vidal I; Bellot P; Gómez-Hurtado I; Zapater P; Such J
Gut; 2016 Jan; 65(1):182-3. PubMed ID: 25832107
[No Abstract] [Full Text] [Related]
7. Saccharomyces boulardii plus rifaximin in mesalamine-intolerant ulcerative colitis.
Guslandi M
J Clin Gastroenterol; 2010; 44(5):385. PubMed ID: 20104184
[No Abstract] [Full Text] [Related]
8. Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system.
Maccaferri S; Vitali B; Klinder A; Kolida S; Ndagijimana M; Laghi L; Calanni F; Brigidi P; Gibson GR; Costabile A
J Antimicrob Chemother; 2010 Dec; 65(12):2556-65. PubMed ID: 20852272
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters.
Kokkotou E; Moss AC; Michos A; Espinoza D; Cloud JW; Mustafa N; O'Brien M; Pothoulakis C; Kelly CP
Antimicrob Agents Chemother; 2008 Mar; 52(3):1121-6. PubMed ID: 18195066
[TBL] [Abstract][Full Text] [Related]
10. Rifaximin for inflammatory bowel disease.
Guslandi M
Dig Dis Sci; 2010 Jun; 55(6):1805. PubMed ID: 20428944
[No Abstract] [Full Text] [Related]
11. Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial.
Kimer N; Pedersen JS; Tavenier J; Christensen JE; Busk TM; Hobolth L; Krag A; Al-Soud WA; Mortensen MS; Sørensen SJ; Møller S; Bendtsen F;
J Gastroenterol Hepatol; 2018 Jan; 33(1):307-314. PubMed ID: 28671712
[TBL] [Abstract][Full Text] [Related]
12. [Clinical and pharmacological aspects of rifaximin, local antibiotic therapy in intestinal disorders].
Gasztonyi B; Hunyady B
Orv Hetil; 2004 Oct; 145(43):2177-81. PubMed ID: 15575494
[TBL] [Abstract][Full Text] [Related]
13. Review--antibiotic treatment in inflammatory bowel disease: rifaximin, a new possible approach.
Gionchetti P; Rizzello F; Venturi A; Ugolini F; Rossi M; Brigidi P; Johansson R; Ferrieri A; Poggioli G; Campieri M
Eur Rev Med Pharmacol Sci; 1999; 3(1):27-30. PubMed ID: 10710827
[TBL] [Abstract][Full Text] [Related]
14. Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps.
Kothary V; Scherl EJ; Bosworth B; Jiang ZD; Dupont HL; Harel J; Simpson KW; Dogan B
Antimicrob Agents Chemother; 2013 Feb; 57(2):811-7. PubMed ID: 23183443
[TBL] [Abstract][Full Text] [Related]
15. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders.
Adachi JA; DuPont HL
Clin Infect Dis; 2006 Feb; 42(4):541-7. PubMed ID: 16421799
[TBL] [Abstract][Full Text] [Related]
16. Rifaximin: in vitro and in vivo antibacterial activity--a review.
Jiang ZD; DuPont HL
Chemotherapy; 2005; 51 Suppl 1():67-72. PubMed ID: 15855749
[TBL] [Abstract][Full Text] [Related]
17. Rifaximin intake leads to emergence of rifampin-resistant staphylococci.
Valentin T; Leitner E; Rohn A; Zollner-Schwetz I; Hoenigl M; Salzer HJ; Krause R
J Infect; 2011 Jan; 62(1):34-8. PubMed ID: 21073894
[TBL] [Abstract][Full Text] [Related]
18. Rifaximin in the treatment of irritable bowel syndrome: is there a high risk for development of antimicrobial resistance?
Farrell DJ
J Clin Gastroenterol; 2013 Mar; 47(3):205-11. PubMed ID: 23340064
[TBL] [Abstract][Full Text] [Related]
19. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria.
Gillis JC; Brogden RN
Drugs; 1995 Mar; 49(3):467-84. PubMed ID: 7774516
[TBL] [Abstract][Full Text] [Related]
20. Role of gut microflora and probiotic effects in the irritable bowel syndrome.
Fanigliulo L; Comparato G; Aragona G; Cavallaro L; Iori V; Maino M; Cavestro GM; Soliani P; Sianesi M; Franzè A; Di Mario F
Acta Biomed; 2006 Aug; 77(2):85-9. PubMed ID: 17172187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
